Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Assessment of Cancer-related Post-traumatic Stress in Patients and Caregivers in the Year Following Diagnosis, and Identification of Their Expectations of Personalized Support - CANDYSTRESS

NCT06944262 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-04-02
Last updated
2026-09-09

Condition(s) studied

CancerHealthcare ProfessionnalsCaregiver DistressCaregiverCaregiver Stress Syndrome

Study summary

The impact of cancer on the lives of patients and their caregivers is undeniable. In addition to the potentially traumatic aspects (i.e., creating a very violent emotional shock) linked to the announcement of the disease and the various stages of the care pathway (effects of treatment, announcement of a cancer recurrence), even before the onset of the disease, patients and their caregivers may have been directly or indirectly confronted with traumatogenic events (e.g., childhood abuse, sudden death). They may therefore be more likely to develop a stress-related mental disorder in their lifetime. The question of the accumulation of traumatic events, the identification of groups of people at risk of developing symptoms of distress, and the management of these symptoms is therefore crucial. In addition, the mutual influence within the patient-caregiver dyad in terms of emotional adjustment, and its evolution throughout the cancer care pathway, are key elements to be considered in these issues.

The CandyStress project is based on a partnership with patients, their caregivers and carers to identify the needs of patient-caregiver dyads at risk of cancer-related post-traumatic stress disorder (Ca-PTS). Longitudinal screening for Ca-PTS in the year following cancer diagnosis will be carried out to identify the characteristics of at-risk dyads who could benefit from long-term support. The aim of this project is to identify the potential need for targeted support and the desired format of this support. This is a preliminary step in identifying needs and the context conducive to the implementation of personalized support, but in no way an evaluation of the effectiveness of an intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Part 1. Diagnosis of Ca-PTS Patient inclusion criteria: * Male or female, 18 years of age or older, * recently (\<4 months) diagnosed with breast, gynecological, testicular or digestive cancer at the time of the announcement visit (i.e., the announcement to the patient of the treatment plan after the initial multidisciplinary consultation meeting in the cancer center - in accordance with the Cancer Plan), * with cancer requiring oncological treatment, * starting oncology treatment at the Oscar Lambret Center, * with no Central Nervous System (CNS) metastases, * with a PRONOPALL score ≤3 (favorable prognosis group, Bourgeois et al., 2017) or expected survival greater than 6 months, * who have given signed consent to participate in the study and are covered by French social security, * able to identify a caregiver (i.e., a family member, friend or other person who has helped care for them since diagnosis). * equipped with a computer or tablet equipped with a webcam and an internet connection, for the online questionnaire - the webcam is only necessary if the participant wants the IGE to be present via video on the computer, if they prefer the video to be made over the phone, in which case they must also be equipped with a smartphone enabling video calls. Inclusion criteria for caregivers: * Male or female, 18 years of age or older, * designated by the patient as their primary caregiver (i.e. "a family member, friend or other person who has helped care for you since diagnosis"), * have given their signed consent to participate in the study. * equipped with a computer or tablet equipped with a webcam and an internet connection, for the online questionnaire - the webcam is only necessary if the participant wishes the IGE to be present via video on the computer, if he/she prefers the video to be made over the phone, in which case it is also necessary to be equipped with a smartphone enabling video calls. Part 2. Gathering expectations for personalized support and its components. In addition, 3 types of focus groups will be set up remote : Focus groups with patients from local associations, as well as patient partners of the Oscar Lambret Center and patients from Part 1 if they are interested. Inclusion criteria for patient focus groups: * Men or women of legal age who have or have had cancer, * Members of a local patient association or of the Oscar Lambret Center's "patient partners" committee, * Or have participated in part 1 (Ca-PTS screening, once the 3 steps have been completed), * Equipped with a computer or tablet with camera and internet connection, * Have given their consent to take part in the study. Focus group with caregivers from local associations as well as "partner caregivers" from the Oscar Lambret Center and caregivers from part 1 if they are interested. Inclusion criteria for "caregiver" focus groups: * Men or women of full age who are, or have been, caregivers of a cancer patient, * members of a local caregivers' association, * or having participated in part 1 (Ca-PTS screening, once the 3 steps have been completed), * Equipped with a computer or tablet with camera and internet connection, * Having given their consent to take part in the study. Focus groups with hospital medical and paramedical staff as well as non-hospital caregivers involved in the medical in the medical and psychological follow-up of patients. Inclusion criteria for caregiver focus groups: * Member of the medical and paramedical staff of the Oscar Lambret Center * Or non-hospital staff involved in the medical or psychological care of patients, * Professionals not involved in the present study, * Equipped with a computer or tablet with camera and internet connection * Having given their consent to participate in the study Exclusion Criteria: Part 1. Diagnosis of Ca-PTS Non inclusion criteria for patients : * Patients with meningeal or cerebral metastases, * Patients with cancer recurrence, * Patients suffering from a psychiatric or neurological disorder likely to impair their ability to reason or judge (in particular psychotic disorder, autism spectrum disorder, intellectual disability), * Patients with a psychological or physical incapacity to answer questionnaires, certified by medical staff, * Patients subject to a custodial sentence, guardianship or protection of vulnerable adults, * Presence of CNS metastases (risk of cognitive impairment preventing completion of questionnaires). Non-inclusion criteria for caregivers: * Caregivers suffering from a psychiatric or neurological disorder likely to impair their ability to reason or exercise judgment judgment (in particular psychotic disorder, autism spectrum disorder intellectual disability), or for whom there is a suspicion (not there is a suspicion (no additional examination is prescribed to confirm this criterion, which remains self-declaratory). * Caregivers with a psychological or physical inability to answer questionnaires, or for whom there is a suspicion suspicion (no further tests are required to confirm this criterion which remains self-reported). * Caregivers subject to a custodial sentence, guardianship or protection guardianship or protection of vulnerable adults. Part 2. Collection of expectations for personalized support and its components. Non-inclusion criteria for patients and caregivers who participated in the screening part of the Ca-PTS : \- Failure to complete all measurement times (T0, T1, T2) Non-inclusion criteria for focus groups (patients, caregivers): none

Primary outcome measure(s)

  • PTSD Checklist for DSM-5 (PCL5) — measured in the month following the announcement of the cancer treatment, then 6 months and 12 months later - in patients and their caregiver
    total score (0-80) reflects the severity of Post Traumatic Stress Disorder (PTSD) symptoms. A score threshold \> 32 has been validated as reflecting probable PTSD

Trial sites (2)

FacilityCityRegionStatus
Centre Oscar Lambret Lille Nord Recruiting
Centre Oscar Lambret Lille Nord Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06944262 on ClinicalTrials.gov ↗ ← All trials in France